We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+56.37%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$17M
Cap. Flow
-$11.6M
Cap. Flow %
-11.47%
Top 10 Hldgs %
53.57%
Holding
52
New
16
Increased
7
Reduced
8
Closed
17

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$5.53M
2
SMMT icon
Summit Therapeutics
SMMT
+$4.78M
3
CDTX
Cidara Therapeutics
CDTX
+$4.37M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.62M
5
IQV icon
IQVIA
IQV
+$3.48M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$7.13M
2
VRNA
Verona Pharma
VRNA
+$6.52M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.1M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.74M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
1
Zai Lab
ZLAB
$2.28B
$6.8M 6.7%
200,628
+65,733
+49% +$2.26M
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
$6.56M 6.46%
+68,463
New +$4.37M
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$5.93M 5.84%
789,646
-497,035
-39% -$3.17M
ETNB
4
DELISTED
89bio
ETNB
$5.65M 5.57%
384,652
+172,275
+81% +$1.76M
IMVT icon
5
Immunovant
IMVT
$8.27B
$5.5M 5.42%
+341,348
New +$5.53M
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$15.5B
$5.39M 5.31%
40,893
-3,214
-7% -$385K
COGT icon
7
Cogent Biosciences
COGT
$6.68B
$5.19M 5.11%
361,408
-601,543
-62% -$7.13M
SVRA icon
8
Savara
SVRA
$1.13B
$4.67M 4.6%
1,309,236
+193,857
+17% +$573K
BBIO icon
9
BridgeBio Pharma
BBIO
$15.9B
$4.6M 4.54%
88,658
-8,108
-8% -$395K
SMMT icon
10
Summit Therapeutics
SMMT
$10.7B
$4.08M 4.01%
+197,253
New +$4.78M
IQV icon
11
IQVIA
IQV
$34.4B
$3.63M 3.58%
+19,114
New +$3.48M
CABA icon
12
Cabaletta Bio
CABA
$461M
$3.61M 3.56%
1,544,525
+483,761
+46% +$830K
REGN icon
13
Regeneron Pharmaceuticals
REGN
$70.9B
$3.6M 3.55%
+6,401
New +$3.62M
DRUG
14
Bright Minds Biosciences
DRUG
$747M
$3.27M 3.22%
+53,950
New +$2.09M
NKTR icon
15
Nektar Therapeutics
NKTR
$2.31B
$2.92M 2.87%
+51,270
New +$1.7M
INSM icon
16
Insmed
INSM
$23.5B
$2.85M 2.81%
19,786
+5,215
+36% +$639K
BCAX
17
Bicara Therapeutics
BCAX
$1.82B
$2.78M 2.74%
175,902
-13,797
-7% -$154K
AVTX icon
18
Avalo Therapeutics
AVTX
$1.02B
$2.39M 2.36%
+188,080
New +$1.62M
SNY icon
19
Sanofi
SNY
$107B
$2.38M 2.34%
+50,407
New +$2.43M
ZBIO
20
Zenas BioPharma
ZBIO
$1.86B
$2.15M 2.11%
96,665
-14,940
-13% -$243K
QURE icon
21
uniQure
QURE
$2.77B
$1.94M 1.91%
+33,175
New +$602K
TECX
22
Tectonic Therapeutic
TECX
$615M
$1.87M 1.84%
119,286
+40,228
+51% +$830K
URGN icon
23
UroGen Pharma
URGN
$1.96B
$1.75M 1.73%
87,912
– –
TARA icon
24
Protara Therapeutics
TARA
$230M
$1.57M 1.54%
360,000
– –
KROS icon
25
Keros Therapeutics
KROS
$211M
$1.5M 1.48%
+95,083
New +$1.4M
1
2 3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Superstring Capital Management held 52 positions worth $102M, up 20% from $84.5M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Superstring Capital Management withdrew a net $11.6M in Q3 2025, closing 17 positions and reducing 8 holdings. Its most notable exit was Verona Pharma, an estimated $6.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Immunovant worth $5.5M.

  • Superstring Capital Management's largest Q3 2025 buy was Immunovant: 341,348 shares worth $5.5M.
  • Superstring Capital Management added most to Zai Lab in Q3 2025, an estimated $2.26M increase.
  • Superstring Capital Management's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $7.13M.
  • Superstring Capital Management fully exited Verona Pharma in Q3 2025, selling an estimated $6.52M.
  • Superstring Capital Management's ten largest holdings make up 54% of its $102M portfolio in Q3 2025.
  • Superstring Capital Management opened 16 new positions and closed 17 in Q3 2025.
  • Superstring Capital Management's portfolio value rose 20% quarter-over-quarter to $102M.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.